Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Beyond the Feasibility Survey: Strategic Site Selection to Accelerate Trials and Optimize Resources Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Reducing Patient Burden in Rare Disease Trials How to Accelerate the Adoption of Decentralized Trials for Rare Disease Indications
Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Beyond the Feasibility Survey: Strategic Site Selection to Accelerate Trials and Optimize Resources Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Reducing Patient Burden in Rare Disease Trials How to Accelerate the Adoption of Decentralized Trials for Rare Disease Indications
